Gene · 7068
Papers3,032
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
1 to 20 of 3,032
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| [New Therapeutic Approaches for MASH: Mechanisms and Clinical Promise]. | Z Gastroenterol | 2026 | 42777699 | PubTator, text mining | PubMed |
| Reporter-guided photoreceptor differentiation in 2D culture using PGP1-hIPSCs: A comparable alternative to 3D organoid systems? | Mol Vis | 2026 | 42774032 | PubTator, text mining | PubMed |
| Combination pharmacotherapy for MASH: Potential synergistic approaches. | Biochem Pharmacol | 2026 | 42767573 | PubTator, text mining | PubMed |
| Evaluation of the Immortalized Primary Human Hepatocyte Cell Line Fa2N-4 as a Model for Metabolic Dysfunction-Associated Steatotic Liver Disease. | Gastro Hep Adv | 2026 | 42755934 | PubTator, text mining | PubMed |
| Prime editing models the MTARC1 A165T variant in human liver organoids, demonstrating reduced steatosis, inflammation, and fibrosis. | Hepatol Commun | 2026 | 42748411 | PubTator, text mining | PubMed |
| MYC-regulated long non-coding RNA SNHG1 controls S-phase kinase-associated protein 2-mediated p21 protein stability under thyroid hormone receptor signaling in hepatocellular carcinoma. | Int J Biol Macromol | 2026 | 42735764 | PubTator, text mining | PubMed |
| Hypothyroidism and Metabolic Dysfunction-Associated Steatotic Liver Disease: Mechanisms, Clinical Links, and Therapeutic Implications. | Curr Obes Rep | 2026 | 42734707 | PubTator, text mining | PubMed |
| International expert panel review for the use of resmetirom and semaglutide in the management of MASH-related fibrosis: clinical practice update. | Gut | 2026 | 42728029 | PubTator, text mining | PubMed |
| The role of thyroid hormone receptor beta 1 (THRβ1) in metabolic dysfunction associated steatohepatitis (MASH): from dysregulation to therapeutic target. | Biochem Pharmacol | 2026 | 42710788 | PubTator, text mining | PubMed |
| Current therapeutic landscape and future treatment perspectives of MASH. | Nature | 2026 | 42687024 | PubTator, text mining | PubMed |
| Integrating the liver into the cardiovascular-kidney-metabolic syndrome: pathophysiology and therapeutic implications. | Curr Opin Nephrol Hypertens | 2026 | 42683763 | PubTator, text mining | PubMed |
| New therapeutic options for metabolic-associated steatotic liver disease. | Br J Clin Pharmacol | 2026 | 42661253 | PubTator, text mining | PubMed |
| ALG-055009 in non-cirrhotic adults with metabolic dysfunction-associated steatohepatitis (HERALD): a randomised, double-blind, placebo-controlled, phase 2a trial. | Lancet Gastroenterol Hepatol | 2026 | 42648297 | PubTator, text mining | PubMed |
| Therapeutic Mechanisms of Resmetirom and Semaglutide in MASLD/MASH: A Review of Inflammatory and Fibrotic Metabolites. | Metabolites | 2026 | 42646322 | PubTator, text mining | PubMed |
| Thyroid-stimulating hormone-secreting pituitary neuroendocrine tumor (TSH-PitNet) diagnosed during pregnancy and treated with a somatostatin analog. | Taiwan J Obstet Gynecol | 2026 | 42642161 | PubTator, text mining | PubMed |
| Screening for candidate genes and cell populations associated with atherosclerotic calcification using single-cell RNA sequencing. | Mamm Genome | 2026 | 42581084 | PubTator, text mining | PubMed |
| Pharmacologic management of metabolic and alcohol-associated liver disease. | Metab Target Organ Damage | 2026 | 42577825 | PubTator, text mining | PubMed |
| The new era of MASH pharmacotherapy: a comprehensive review of FDA-approved and emerging agents. | Front Gastroenterol (Lausanne) | 2026 | 42564069 | PubTator, text mining | PubMed |
| Resmetirom Ameliorates Fibrogenesis in Hepatic Stellate Cells via Thyroid Hormone Receptor Alpha-Fatty-Acid Amide Hydrolase 1 Signaling Pathway. | MedComm (2020) | 2026 | 42558980 | PubTator, text mining | PubMed |
| Resmetirom and semaglutide: next-generation therapies for metabolic-associated steatohepatitis. Opportunities, challenges and issues. | Expert Rev Endocrinol Metab | 2026 | 42552573 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/7068/papers